Categories: HealthDay

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

TUESDAY, June 5, 2018 (HealthDay News) — The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

A biosimilar drug, generally derived from a living organism, is approved based on clinical evidence that it is “highly similar” to a product that’s already approved by the FDA, and that there are “no clinically meaningful differences” in safety, purity and potency, the agency said.

The most common side effects of Fulphila are pain in the bones, arms and legs. Less common but more serious adverse reactions include the possibility of spleen rupture, severe respiratory problems and allergic reactions, glomerulonephritis, leukocytosis, tumor growth, and “fatal sickle cell crises,” the FDA said.

“We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from [price] competition to existing biologics once lawful intellectual property has lapsed on these products,” FDA Commissioner Scott Gottlieb, M.D., said in a statement.

Fulphila is produced by Mylan, with U.S. headquarters in Canonsburg, Penn.

More Information

Copyright © 2018 HealthDay. All rights reserved.

Physicians Weekly

Recent Posts

  • Reuters

J&J moves to limit impact of Reuters report on asbestos in Baby Powder

By Mike Spector NEW YORK (Reuters) - Johnson & Johnson on Monday scrambled to contain fallout from a Reuters report…

25 mins ago
  • Reuters

More U.S. adults may be trying to lose weight, after all

By Lisa Rapaport (Reuters Health) - - Researchers said last year that the proportion of overweight U.S. adults trying to…

40 mins ago
  • Reuters

FDA panel backs prescribing opioid overdose reversal drug along with painkillers

By Saumya Joseph and Manas Mishra (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Tuesday…

1 hour ago
  • Reuters

Teen pot users may hallucinate, become paranoid

By Lisa Rapaport (Reuters Health) - - More than two in five teens who use marijuana experience psychotic symptoms like…

2 hours ago
  • Reuters

New Hampshire physician assistant guilty of Insys opioid kickback scheme

By Nate Raymond (Reuters) - A former physician assistant in New Hampshire was convicted on Tuesday of charges that he…

4 hours ago
  • Doctor's Voice
  • Skeptical Scalpel

Kidney trouble

Last month, I blogged about an unfortunate Florida woman who had a normal kidney removed because a surgeon thought it…

4 hours ago
avtomaticheskij-poliv.com.ua

красивые детские платья

www.niko-centre.kiev.ua